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Major challenge for the Western Balkan pharmaceutical markets remains legal enforcement of
measurable tender criteria (1) when submitting offers for supplying large healthcare centers. All of
regional economies increased health spending rapidly over past two and a half decades.Nevertheless,
constrained national drug budgets have led to the development of diverse resource allocation
strategies (2). Public debate has created an impression that there is room for more active inclusion of
marketing in generating strategic decisions at the company level (3). Focus on operative, daily duties
may also be the result of the complex and difficult conditions in which the pharmaceutical industry
functions in Serbia (4). This market is characterized by modest size, decent growth rates, and
heavy domination of generics as compared to other Eastern European countries (5). Local industry
balances between imposed legislative limitations, its own orientation to generating profit, and de
facto present social and ethical factor. Value creation in domestic market is unified in synergetic
effect of the product, pricing, distribution, and promotion (6). A superior competitive strategy must
be sought at the enhanced product level, i.e., in the concept of value added, where companies on the
market of Serbia are only making their first steps (7).
A networked environment may serve as a useful framework for a brand new view of the roles
of individual stakeholders, once again with the aim to maximize the outputs of healthcare system.
There is also the traditional lag existing in the arrival of innovation to the market of Serbia. It is
not characteristic of the pharmaceutical industry, but rather results from the fact that recent years
have seen an evident lag of Serbian economy behind global trends, manifested in the delayed effect
of the global economic crisis (8). Suppliers on the Serbian market argue that patient education
is the responsibility of the healthcare system. The practices of pharmaceutical companies in the
markets of developed countries testify to a new, more active role of the pharmaceutical industry
in this education (9). Opinions on direct promotion speak that originators of supply on the
Serbian market do not see patients as “legitimate target” of the industry’s marketing effort, which
is in accordance with the marketing practices elsewhere in liberal, less regulated, high-income
markets (10).
Based on published evidence, it can be concluded that there is a significant potential for improving
the marketing function, its place and role, and the resulting marketing activities (11). As cited,
contemporary research included 30 companies on the territory of the Europe, the problems faced,
and conclusions presented correspond closely to the results of qualitative research conducted on 10
participants on the pharmaceutical market of Serbia (12).The common premise is that the European
market is far more developed and matured in terms of the application of marketing. Government
regulations on pricing and the objective permanence of distribution channels prevent pharmaceuti-
cal companies from viewing them as active marketing mix elements. The socio-political element is
especially manifested in the domain of price control (13). Formalized process of adoptingmarketing
strategies may be potentially successful in certain market conditions and specific corporate culture.
Change in conditions may valorize different approaches to planning and implementing marketing
strategies. It appears that different degrees of formalization of adopting marketing strategies and
a different position and role of marketing within an organization may result in equally successful
pharmaceutical companies. Companies that participated in the research in Serbia achieved their
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leading position through successful adaptation to changed
conditions. Nevertheless, the process of transformation in the
environment and the organization is permanent (14). Some of the
respondents very objectively assessed that changes in the business
conditions and organization also imply new behavior patterns
in order to accomplish the objectives (15). Further acceleration
of population aging and growth of global emerging markets
reshaping health care landscape worldwide will give the long-term
imprint to the pharmaceutical markets evolution in small nations
bordering EU’s economic zone (16).
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